Abstract: A method of treating osteoporosis comprising administering to a subject a composition comprising a compound, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or a salt thereof, is described. A method of inhibiting osteoclast activity and stimulating osteoblast activity in a subject also is described.

Abstract: A lighting device may be provided that includes a case including: a bottom plate; walls extending from ends of the bottom plate; and louvers coupled to and inclined from respective edges of the walls; a light emitter disposed on the bottom plate; and a diffuser plate spaced apart from the light emitter and disposed between the walls, wherein each of the louvers is oriented at an obtuse angle relative to the diffuser plate and wherein the light emitter includes an LED.

Abstract: The present invention relates to novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same. The novel benzamidine derivatives of the present invention are useful for the prevention and treatment of osteoporosis, bone fractures and allergic inflammatory diseases.

Abstract: A lighting device includes a first lighting module, a second lighting module, a case coupled to the first and second lighting modules, and a power circuit between the first and second lighting modules. Each of the first and second lighting modules includes a plurality of light emitting diodes (LEDs), and bottom surfaces of the first and second lighting modules and the power circuit are aligned on substantially a same plane.

Abstract: A semiconductor memory device includes cells strings including memory cells and coupled between a common source line and bit lines, respectively, a peripheral circuit configured to store data in the memory cells or read data stored in the memory cells, a main voltage supply unit configured to generate operating voltages to be supplied to the peripheral circuit, a precharge voltage supply unit configured to generate a precharge voltage for precharging the bit lines, and a switching circuit configured to transfer the precharge voltage to the common source line and one of the bit lines when a bit line precharge operation is performed.

Abstract: The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing same, a pharmaceutical composition for prevention and treatment of osteoporosis including same, applications of same for preparing the therapeutic agent of osteoporosis prevention and treatment, and a method for prevention and treatment of osteoporosis using same. The 2,6-substituted-3-nitropyridine derivative compound of the present invention effectively increases osteoblast activity and also inhibits the formation of osteoclasts, so that it may be usefully used for the prevention and treatment of osteoporosis.

Abstract: The object of the present invention is to provide a therapeutic agent or a prophylactic agent for a disease resulting from an abnormal bone metabolism, especially osteoporosis which is more effective than conventional agents. Excellent therapeutic effect or prophylactic effect on a disease resulting from an abnormal bone metabolism, especially osteoporosis, compared with the effect in administration of each compound alone can be obtained by the combination of an N-hydroxybenzamidine derivative represented by Formula (I) or a salt thereof with an activated vitamin D or a prodrug thereof.

Abstract: The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing the same, and a pharmaceutical composition including the same for prevention and treatment of osteoporosis. The 2,6-substituted-3-nitropyridine derivative compound of the present invention increases osteoblast activity and effectively inhibits the differentiation of osteoclasts, and thus can be usefully used for the prevention and treatment of osteoporosis.

Abstract: The present invention provides a method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivative or its salt, and bisphosphonate for the purpose of using simultaneously, separately, or sequentially as active ingredients. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of the benzamidine derivative and the bisphosphonate compound exhibits excellent inhibitory effect on osteoclast differentiation than the total effect of each individual treatment, thereby being used for the prevention or treatment of osteoporosis.

Abstract: Disclosed is a light source device. The light source device includes: a light guide plate; a reflector disposed under the light guide plate; a light source unit optically coupled to the light guide plate; and a photo luminescent film disposed between the light guide plate and the light source unit, wherein the photo luminescent film includes at least two partitioned areas, and wherein a first fluorescent material included in at least one area of the at least two areas is different from a second fluorescent material included in the other areas.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating osteoporosis, comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, or salts thereof, and alendronic acid or a salt thereof. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or salts thereof and alendronic acid or a salt thereof exhibits excellent inhibitory effect on osteoclast differentiation, as compared to each individual treatment, thereby being useful for the prevention or treatment of osteoporosis.

Abstract: The present invention relates to a novel benzamidine derivative, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzamidine derivative of the present invention effectively inhibits osteoclast differentiation at an extremely low concentration, and greatly increases the trabecular bone volume, and thus it can be advantageously used for the prevention and treatment of osteoporosis.

Abstract: A lighting device includes a first lighting module, a second lighting module, a case coupled to the first and second lighting modules, and a power circuit between the first and second lighting modules. Each of the first and second lighting modules includes a plurality of light emitting diodes (LEDs), and bottom surfaces of the first and second lighting modules and the power circuit are aligned on substantially a same plane.

Abstract: The present invention relates to novel benzamidine derivatives, a process for the preparation thereof and a pharmaceutical composition for preventing or treating osteoporosis comprising the same. The benzamidine derivatives of the present invention effectively inhibit osteoclast differentiation at an extremely low concentration, and thus can be advantageously used for the prevention and treatment of osteoporosis.

Abstract: A hydrocarbon reforming catalyst includes an oxide support as well as a nickel active catalyst layer, a metal oxide, an alkali metal supported by the oxide support.

Abstract: A hydrocarbon reforming catalyst, a method of preparing the hydrocarbon reforming catalyst, and a fuel cell including the hydrocarbon reforming catalyst. The hydrocarbon reforming catalyst includes a nickel active catalyst layer loaded on an oxide carrier, and a metal oxide.

Abstract: This invention relates to a pharmaceutical composition containing 4-[(4-thiazolyl)phenoxyl]alkoxy-benzamidine derivatives expressed by the following formula 1 for the prophylaxis and treatment of osteoporosis and more particularly, to the use of 4-{5-[4-(5-isoproply-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine expressed by the following formula 1 as a pharmaceutical composition for the prophylaxis and treatment of osteoporosis.

Abstract: An exemplary fuel cell of the invention includes a formic acid fuel solution in communication with an anode (12, 134), an oxidizer in communication with a cathode (16, 135) electrically linked to the anode, and an anode catalyst that includes Pd. An exemplary formic acid fuel cell membrane electrode assembly (130) includes a proton-conducting membrane (131) having opposing first (132) and second surfaces (133), a cathode catalyst on the second membrane surface, and an anode catalyst including Pd on the first surface.

Abstract: A method of treating osteoporosis comprising administering to a subject a composition comprising a compound, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or a salt thereof, is described. A method of inhibiting osteoclast activity and stimulating osteoblast activity in a subject also is described.

Abstract: This invention relates to a pharmaceutical composition containing 4-[(4-thiazolyl)phenoxyl]alkoxy-benzamidine derivatives expressed by the following formula 1 for the prevention and treatment of osteoporosis and more particularly, to the use of 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-iso-propyl-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine expressed by the following formula 1, which is known as an antagonist of leukotriene-B4 receptor, as a pharmaceutical composition for the prevention and treatment of osteoporosis. [Formula 1], wherein, R is a hydrogen atom or a hydroxy group.